🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsVendor Reviews[REVIEW] Tailor Made Compounding — need advice

[REVIEW] Tailor Made Compounding — need advice

denise_HTX Mon, Feb 2, 2026 at 5:45 AM 39 replies 1,218 viewsPage 1 of 8
denise_HTX
Member
145
678
Jan 2025
Houston, TX
Feb 2, 2026 at 5:45 AM#1

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

What I actually want to know is why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission.

Numbers rather than impressions, if you have them.

3 23sarah.morrison, NeuroNate, JessicaH_TX
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Feb 2, 2026 at 5:59 AM#2

Short answer first, then the reasoning. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

2 22pam_stl, wei_SG
Reply Quote Save Share Report
MarkLI_maint
Member
534
2,345
Jun 2024
Long Island, NY
Feb 2, 2026 at 6:13 AM#3
Dr.RenalNash said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

That is correct as far as it goes, and here is where it stops going. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.

1 21HPLC_Greg
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
amy_econ_NJ
Member
567
2,567
May 2024
Princeton, NJ
Feb 2, 2026 at 6:27 AM#4
denise_HTX said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Same position here, arrived at the long way round. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

I would rather be corrected than agreed with, if it comes to it.

Last edited: Feb 2, 2026 at 9:27 AM
50 20gary_naperville, sean_dublin, hannah_MT and 47 others
Reply Quote Save Share Report
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
Feb 2, 2026 at 7:39 AM#5

From the other side of the consultation, briefly.

Price comparison for compounded supply across sources I've used:

SourceMonthly CostTypePurity Verified
Brand (Ozempic)$905FDA-approvedN/A (pharma)
503B Compounding$135cGMP compoundedYes (in-house)
503A Compounding$95Patient-specificVaries
Research peptide$45Not for human useOften Janoshik

I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.

49 19kim_atl_prep, sarah_TO, wendy_avl and 46 others
Reply Quote Save Share Report
1238

Similar Threads

[REVIEW] WWB — 8 months, 6 orders, all Janoshik tested7 replies
[REVIEW] QSC — consistency and pricing, 10+ orders deep5 replies
[REVIEW] GGPeps — 6 orders, all independently tested3 replies
Which vendor should I go with? Side-by-side comparison3 replies
How do you vet a new vendor? My quality checklist9 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register